Managing Drug-Resistant Autosomal Dominant Nocturnal Frontal Lobe Epilepsy After Failure of Alternative Antiepileptic Therapy
This protocol addresses patients with autosomal dominant nocturnal frontal lobe epilepsy whose nocturnal seizures have not responded adequately to alternative or add-on antiepileptic treatment, establishing drug resistance and the need for a next-line approach.
Prior Treatment Failure
Alternative or add-on antiepileptic therapy — including agents such as topiramate, oxcarbazepine, acetazolamide, and nicotine transdermal patches — did not achieve seizure freedom or at least a 50% reduction in nocturnal seizure frequency. Failure to reach these goals defines drug resistance and triggers escalation to this protocol.
Next-Line Approach
For carefully selected drug-resistant patients, this protocol covers a resective surgical treatment pathway. Specific eligibility criteria and a structured presurgical evaluation are required before proceeding — the complete evaluation pathway, selection criteria, and full protocol details are in the structured regimen.
Treatment Goal
Complete seizure freedom at 12 months after surgery.
References
DOI: 10.1007/s11910-013-0424-6
- Surgical treatment may provide excellent results for selected drug-resistant NFLE patients both for seizures and for epilepsy-related sleep disturbances, such as fragmented sleep and excessive daytime somnolence.
- An in-depth presurgical evaluation, often including invasive recording by stereo EEG, is mandatory for resective surgery.
- In a population of 21 drug-resistant NFLE patients, after at least 12 months following surgery, 76% of patients were completely seizure-free and the remainder reported significant improvements in seizure frequency and/or intensity.